Related references
Note: Only part of the references are listed.Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes
Tadashi Iwao et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Recent advances in incretin-based therapies
David Russell-Jones et al.
CLINICAL ENDOCRINOLOGY (2012)
Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Circulating Dopamine and C-Peptide Levels in Fasting Nondiabetic Hypertensive Patients The Graz Endocrine Causes of Hypertension study
Andreas Tomaschitz et al.
DIABETES CARE (2012)
Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes
P. Bowman et al.
DIABETIC MEDICINE (2012)
The impact of gender on urine C-peptide creatinine ratio interpretation
Nicholas J. Thomas et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2012)
Incretin Effects on β-cell Function, Replication, and Mass The human perspective
Alan J. Garber
DIABETES CARE (2011)
Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
Urd Kielgast et al.
DIABETES CARE (2011)
Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes
Rachel E. J. Besser et al.
DIABETES CARE (2011)
Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Mathijs C. Bunck et al.
DIABETES CARE (2011)
Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit
K. Y. Thong et al.
DIABETES OBESITY & METABOLISM (2011)
Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies
Anthony Stonehouse et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes
Vandana S. Raman et al.
DIABETES CARE (2010)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
Stability and Reproducibility of a Single-Sample Urinary C-Peptide/Creatinine Ratio and Its Correlation with 24-h Urinary C-Peptide
Tim J. McDonald et al.
CLINICAL CHEMISTRY (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Pregnancy-Induced Rise in Serum C-Peptide Concentrations in Women With Type 1 Diabetes
Lene Ringholm Nielsen et al.
DIABETES CARE (2009)
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2009)
Exenatide efficacy and safety: a systematic review
S. L. Norris et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
T. Vilsboll et al.
DIABETIC MEDICINE (2008)
Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values
Andrew S. Levey et al.
CLINICAL CHEMISTRY (2007)
Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies
B Ahrén et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Share Paper
